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Abstract:  In this work, polymeric nanoparticles containing Pregabalin was prepared and optimized the ideal 
concentration of polymer based on its in vitro release profile for a period of 24hrs.The nanoparticles were 
prepared by solvent displacement method using various concentrations of Eudragit S100 (EPNP1-EPNP5). 
The prepared nanoparticles were characterized for its particle size, zeta potential, drug content, entrapment 
efficiency and invitro drug release profile. The preformulation study results confirmed the compatibility 
between the drug and other excipients used in the formulation. The optimized formulation was selected based 
on its particle size, entrapment efficiency and in vitro drug release profile. The formulation which contains 
300mg of Eudragit S100 (EPNP5) was selected as optimized concentration for the controlled release of 
Pregabalin  for a period of 24hrs. 
 
 
Index Terms- Pregabalin,  Eudragit S100, Polymeric nanoparticles,  Zeta potential,  Encapsulation 
efficiency. 
 
 
I. INTRODUCTION 
The aim of the present work is to develop a controlled release formulation for an antiepileptic drug 
Pregabalin which is considered as one of the primary drug used in the treatment of neuropathic pain 
and epilepsy. [1] 
Pregabalin  on continuous usage (150 – 600mg/day), is reported to cause severe adverse effects 
including dizziness, drowsiness, blurred vision, increased appetite, euphoria, constipation, vomiting, 
erectile dysfunction etc and it is required to be taken three times a day.[2-5] These biological situation 
demand the formulation of Pregabalin loaded Eudragit S100 nanoparticles to achieve controlled 
release for a period of 24hrs which in turn reduces the complications of dose size, dosing frequency, 
adverse effects and improves better patient compliance.  
The biological half-life of Pregabalin is 6 hrs, it needs to be taken frequently in order to maintain the 
steady state blood level concentration. This can be overcome by formulation of controlled release 
nanoparticles of  Pregabalin. 
To achieve the objectives the plan is executed to formulate controlled release Pregabalin nanoparticles 
using Eudragit S100. 
 
II. MATERIALS AND METHODS 
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2.1Materials Used 
Pregabalin , Eudragit S100  and Poloxamer were purchased from Sigma Aldrich. Ethanol was 
purchased from Chemika-Biochemika-Reagents, Mumbai. All other chemicals and reagents used 
were of analytical grade. 
2.2Methods  
2.2.1Preparation of Pregabalin loaded Eudragit S100 nanoparticles 
Solvent displacement method was adopted for the preparation of Pregabalin loaded nanoparticles 
using various concentration of Eudragit S100 as polymer.[6,7,8] Eudragit S100 in various 
concentrations were dissolved with 20ml of ethanol in a beaker. Pregabalin 100mg was dissolved in a 
25ml of distilled water. The drug solution was then injected to the above polymeric solution under 
magnetic stirring. The solution was stirred up to 2 hrs until end point is attained. The water and 
ethanol was evaporated under reduced pressure and final volume is adjusted to 50ml. Several batches 
namely (EPNP1, EPNP2, EPNP3, EPNP4, EPNP5) were formulated by changing the drug and 
polymeric ratio and the effect of polymer concentration on the encapsulation efficiency, particle size 
and in vitro drug release were studied. 
Table 1: Formula used for the preparation of Pregabalin loaded Eudragit S100 nanoparticles 
S.No Trials Pregabalin 
(mg) 
 
Eudragit S100 
(mg) 
Poloxamer 
(mg) 
Ethanol 
(ml) 
Purified 
Water (ml) 
1. EPNP1 100 100 200 20 20 
2. EPNP2 100 150 200 20 20 
3. EPNP3 100 200 200 20 20 
4. EPNP4 100 250 200 20 20 
5. EPNP5 100 300 200 20 20 
 
2.2.2 Characterization Studies  
2.2.2.1 Particle size and Surface charge 
Surface charge is important in adhesion and interaction of particle with cells.[7] The zeta- potential   
is used to measure the cell surface charge density. It can be measured using Malvern zeta sizer. The 
prepared nanoparticles were evaluated for their particle size and surface charge by photon correlation 
spectroscopy (PCS) using zetasizer. [9] 
2.2.2.2 Drug content 
2.2.2.2.1 Standard Preparation 
100mg of Pregabalin standard was weighed accurately and transferred into a 25ml volumetric 
standard flask and dissolved with 5ml of pH 6.8 phosphate buffer. 1ml of this solution was diluted 
with 25 ml with pH 6.8 phosphate buffer. 
2.2.2.2.2 Sample Preparation 
Weighed accurately Pregabalin nanoparticles equivalent to 100mg of Pregabalin and transferred in to 
a 25 ml standard flask. The sample was dissolved with 5 ml of pH 6.8 phosphate buffer and diluted to 
25 ml with pH 6.8 phosphate buffer.1ml of this solution was diluted to 25ml with buffer solution. 
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Then the standard and sample absorbance was measured at 210 nm using a UV-Visible 
spectrophotometer. The percentage of drug content was calculated. 
 
2.2.2.3 Entrapment Efficiency 
The drug loaded nanoparticles were exposed to centrifugation at 15000 rpm for 30 min.[10, 11] The 
supernatant liquid was separated and 1ml of this solution was diluted with water and the absorbance 
was measured at 210 nm. The amount of Pregabalin un-entrapped in the supernatant was calculated. 
The amount of Pregabalin entrapped was determined by subtracting amount of free un-entrapped 
Pregabalin from the total amount of Pregabalin taken for the preparation.  
The formula used to calculate entrapment efficiency was given below [12] 
 
2.2.2.4 In vitro release 
In vitro release studies were performed for 24hrs by using the Franz diffusion cell. [13-16] The 
prepared Pregabalin nanoparticles formulations equivalent to 100mg of Pregabalin were placed inside 
a dialysis membrane and immersed in pH 6.8 phosphate buffer. At predetermined time intervals the 
sample was withdrawn and the amount of Pregabalin released was determined by measuring the 
absorbance at 210 nm using a UV-Visible spectrophotometer. From the absorbance values the 
cumulative percentage drug release was calculated.  
 
  
Figure.1-2. pregabalin loaded eudragit s 100 nanoparticles (EPNP1-EPNP5) 
 
III. Result and Discussion 
3.1 Drug content and entrapment efficiency 
Particle size and entrapment efficiency of the Pregabalin nanoparticles (EPNP1- EPNP5) were 
increased with increasing Eudragit S100 concentration.[12] This may be due to high amount of 
availability of  Eudragit S100 to encapsulate the drug, upon increasing the Eudragit S100 content, 
number of layers coated the drug was increased, this resulted in increased particle size and entrapment 
efficiency. Further increase in the Eudragit S100 concentration (EPNP5), there is no much increase in 
the entrapment efficiency due to the availability of the drug to be incorporated is low which is not 
enough for further encapsulation of drug by Eudragit S100. 
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Table 2: Drug content and entrapment efficiency Particle size and zeta potential of Pregabalin 
nanoparticles. 
Trials Zeta potential 
(mV) 
Particle size 
(nm) 
Entrapment Efficiency 
(%) 
Drug Content 
(%) 
EPNP1 4.75 187.0 72.46±0.24 99.67±0.08 
EPNP2 10.6 663.4 77.89±0.08 99.56±0.24 
EPNP3 6.33 129.8 86.47±0.09 99.38±0.31 
EPNP4 1.73 139.7 90.83±0.15 99.62±0.27 
EPNP5 0.277 117.3 95.07±0.45 99.71±0.19 
 
Table 3: In vitro release studies of Pregabalin nanoparticles 
 
3.2 In- vitro drug release 
 From the in vitro drug release study results, the maximum  percentage drug release (99.58± 0.08) at 
the end of 24hrs was observed with trial EPNP5 which contains 300 mg of Eudragit S100.  
Below 300 mg of Eudragit S100 concentration as in the case of trials EPNP1, EPNP 2,EPNP 
3 and EPNP 4, the maximum percentage drug release 98.54± 0.34, 98.57± 0.19,98.56± 0.11and 
98.57± 0.64were obtained at the end of 12, 16,20 and 24hrs respectively which was not desirable. 
 
 
S.NO TIME 
(Hrs)  
% CUMULATIVE DRUG RELEASE 
EPNP1 EPNP2 EPNP3 EPNP4 EPNP5 
1 0.5 25.56± 0.08 22.46± 0.09 18.45± 0.45
  
13.37± 0.64 11.38± 0.31 
2 1 43.67± 0.34 40.58± 0.31 35.53± 0.27 30.75± 0.15 22.45± 0.27 
3 6 75.57± 0.12 71.79± 0.19 67.85± 0.76 61.44± 0.40 54.29± 0.38 
4 12 98.54± 0.34 93.72± 0.38 81.36± 0.28 73.65± 0.29 68.76± 0.17 
5 16 98.51± 0.27 98.57± 0.19 92.49± 0.38 85.73± 0.17 80.47± 0.28 
6 20 98.48± 0.55 98.54± 0.17 98.56± 0.11 93.42± 0.53 91.39± 0.26 
7 24 98.47± 0.32 98.52± 0.21 98.55± 0.28
  
98.57± 0.64 99.58± 0.08 
mean±S.D, n=3 
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Sample ID Particle size Zeta potential 
EPNP1 
 
 
EPNP2 
 
 
EPNP3 
  
EPNP4 
  
EPNP5 
  
 
Figure.3-12. Particle size and Zeta potential 
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Beyond 250 mg of Eudragit S100 concentration, reduction in drug release was observed in the 
case of trial EPNP5. The maximum percentage drug release for EPNP5 was found to be 99.58± 0.08at 
the end of 24hrs were obtained.  
From the in vitro drug release data for EPNP1- EPNP5, it was observed that increase in 
Eudragit S100 concentration delays the drug release due to increased particle size and reduced surface 
area available for drug release. 
From all the formulations, EPNP5  was selected as best formulation due to its ideal particle size (nm), 
high entrapment efficiency (95.07±0.45%) and desirable drug release (99.58± 0.08% at 24 h). 
 
 
Fig. 13 % Cumulative drug release of Pregabalin loaded Eudragit S 100 nanoparticles (EPNP1 
to EPNP5) 
IV. CONCLUSION 
 
In the present study Eudragit S100 nanoparticles containing Pregabalin was prepared by solvent 
displacement technique. The effect of increase in polymer concentration in various parameters like 
particle size, zeta potential, entrapment efficiency and in vitro release profile were studied. The results 
showed that the in vitro drug release for EPNP1, EPNP2, EPNP3, EPNP4 and EPNP5 were found to 
be 98.47± 0.32, 98.52± 0.21, 98.55± 0.28, 98.57± 0.64 and 99.58± 0.08 respectively. Based on the in 
vitro drug release profile of Pregabalin nanoparticles formulations (EPNP1-EPNP5) EPNP5 was 
selected as the best formulation in which the particle size was 117.3nm and drug:polymer in the ratio 
of 1:3 (Pregabalin 100mg:300mg of Eudragit S100).The in vitro % drug release of EPNP5 
formulation was 99.58± 0.08 and it was found to be suitable formulation for the epileptic patient to 
manage the symptoms of epilepsy. Hence it can be concluded that the newly formulated Pregabalin 
loaded Eudragit S 100 nanoparticles may be ideal and effective to control the epilepsy by allowing the 
drug to release continuously for 24 hrs. 
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